Loading
DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil.
CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Fluorouracil, Capecitabine, Tegafur and Leucovorin. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes clinical 0.94, affected pathway 0.94, literature 0.87, genetic association 0.33, somatic mutation 0.23, animal model 0.38).
In plain words · DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.
DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine.
1 product aims at DPYD: other agents. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA DPYD: RNA tissue enhanced (liver 64 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Head and neck squamous cell carcinoma, Gastric & gastro-oesophageal junction cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (gastric cancer). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas DPYD tissue; Open Targets ENSG00000188641 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Lu Z.-H. et al, J. Biol. Chem, 1992, "Purification and characterization of dihydropyrimidine dehydrogenase from human liver". Source.
Sources: HGNC HGNC:3012 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q12882 (protein name, function text, keywords and locations (REST API)); CIViC gene DPYD (4 evidence items, 0 assertions, 4 variants; diseases: Cancer, Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000188641 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: gastric cancer 0.54 (GraphQL API, CC0))
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil. Location: Cytoplasm, cytosol (UniProt). Locus 1p21.3 (HGNC).
RNA: tissue enhanced (liver 64 nTPM), detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA DPYD tissue · HPA DPYD pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
All three of the active bowel cancer chemotherapy drugs given together instead of two. It shrinks more tumours than a doublet and is chosen when shrinking the tumour is what matters, usually with bevacizumab.
Query for this target: (TITLE:"DPYD" OR ABSTRACT:"DPYD" OR TITLE:"dihydropyrimidine dehydrogenase" OR ABSTRACT:"dihydropyrimidine dehydrogenase" OR TITLE:"Dihydropyrimidine dehydrogenase [NADP + ]" OR ABSTRACT:"Dihydropyrimidine dehydrogenase [NADP + ]" OR TITLE:"DHPDHase" OR ABSTRACT:"DHPDHase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DPYD, not a curated reading list.
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), CIViC.